Anti-CD45RB monoclonal antibody

Drug Profile

Anti-CD45RB monoclonal antibody

Alternative Names: Anti-CD45RB monoclonal antibody MB23G2; Monoclonal antibody MB23G2

Latest Information Update: 16 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen; University of Groningen; University of Western Ontario
  • Class Monoclonal antibodies
  • Mechanism of Action CD45 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 28 Jun 2004 This monoclonal antibody is still in active development
  • 19 Jan 1999 Two preclinical studies have been added to the pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top